Clinical Significance of Heme Oxygenase 1 in Tumor Progression

Antioxidants

Nicola Traverso¹  Caterina Ivaldo¹  AnnaLisa Furfaro¹  Mariapaola Nitti¹ 

[1] Department of Experimental Medicine, University of Genoa, Via L.B. Alberti 2, 16132 Genova, Italy;

关键词: HO-1;    Nrf2;    cancer progression;    patients;    therapy;    prognosis;   

DOI  :  10.3390/antiox10050789

来源: DOAJ

【 摘 要 】

Heme oxygenase 1 (HO-1) plays a key role in cell adaptation to stressors through the antioxidant, antiapoptotic, and anti-inflammatory properties of its metabolic products. For these reasons, in cancer cells, HO-1 can favor aggressiveness and resistance to therapies, leading to poor prognosis/outcome. Genetic polymorphisms of HO-1 promoter have been associated with an increased risk of cancer progression and a high degree of therapy failure. Moreover, evidence from cancer biopsies highlights the possible correlation between HO-1 expression, pathological features, and clinical outcome. Indeed, high levels of HO-1 in tumor specimens often correlate with reduced survival rates. Furthermore, HO-1 modulation has been proposed in order to improve the efficacy of antitumor therapies. However, contrasting evidence on the role of HO-1 in tumor biology has been reported. This review focuses on the role of HO-1 as a promising biomarker of cancer progression; understanding the correlation between HO-1 and clinical data might guide the therapeutic choice and improve the outcome of patients in terms of prognosis and life quality.

【 授权许可】

Unknown